- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02619773
Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery
The Use of Mupirocin Dressings and Its Effect on Surgical Site Infections in Elective Colorectal Surgery: A Prospective, Randomized Controlled Trial
Infections at the site of surgical incisions (SSIs) are the most common infection among surgical patients. Although all patients undergoing surgical procedures are at risk for developing SSIs, colorectal surgery has had consistently had high rates of SSIs, ranging from 3-45%. These infections can increase the length of hospital stay, and increase the rate of readmissions and costs.
Further research is needed to study the effects of mupirocin in general surgery. A recent study compared colorectal SSI rates between mupirocin and standard gauze surgical dressings. The results of this show that mupirocin has the greatest effect on reducing SSI rate when compared to standard gauze dressings. However, these studies have not been performed in the United States and have only been studied on a very specific patient population.
The purpose of this study is to assess the rate of infections at the surgical incision after colorectal surgery when a mupirocin dressing is placed versus a standard gauze dressing without mupirocin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Surgical site infections (SSIs) are the most common nosocomial infection among surgical patients and are the third most common nosocomial infection among all hospitalized patients.1 Although all patients undergoing surgical procedures are at risk for developing SSIs, colorectal surgery has consistently had high rates of surgical site infections, ranging from 3-45%. Numerous studies have shown the adverse effects of SSIs, including increased length of hospital stay, morbidity, mortality, readmissions and costs. In a recent study analyzing various surgical procedures, including colorectal operations, surgical site infection was found to be the number one cause of unplanned readmission.
Studies have been performed showing that intranasal mupirocin may have a role in reduction of SSI in cardiac and orthopedic surgery. However, there has been minimal investigation on the effects of topical mupirocin in general surgery. A recent study from Spain compared colorectal SSI rates between mupirocin dressings, silver-impregnated dressings, and standard gauze surgical dressings. The results of this show that mupirocin has the greatest effect on reducing SSI rate when compared to standard gauze and silver-impregnated dressings. However, these studies have not been performed in the United States and have only been studied on open, colorectal oncologic surgery.
The aim of this study is to compare mupirocin dressings to standard surgical dressings and their respective SSI rates at a United States community hospital in patients undergoing elective open and minimally invasive colorectal surgery.
A single-center prospective, randomized study will be performed. Patients who will undergo elective colorectal surgery and consent to participate will be randomized (1:1) to one of the following 2 treatment groups:
- Island dressings until postoperative day (POD) #2 (which is current practice at Gundersen Health System)
- Mupirocin + island dressing until POD#5 Analysis of outcomes will include rate of SSI, and 30-day morbidity and mortality.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
La Crosse, Wisconsin, United States, 54601
- Gundersen Lutheran Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Elective Colorectal surgery
- Open and minimally invasive cases
- Partial and total Colon resections, Abdominoperineal resection, Low anterior resections, Creation/takedown of colostomy, abdominal procedures for prolapse
Exclusion Criteria:
- Patients with known allergies to mupirocin
- Cases in which the skin was intentionally left open at the end of surgery (secondary closure technique)
- Women who are pregnant or planning to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mupirocin dressing
Mupirocin + island dressing applied to surgical incision until postoperative day 5. Intervention: mupirocin ointment applied to extrication incision. |
Mupirocin ointment will be applied after skin closure.
A standard island dressing will be placed over the incision.
|
|
No Intervention: Island dressing
Island dressing applied to surgical incision until postoperative day 2.
This arm will not undergo any intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical Site Infection
Time Frame: within 30 days postoperative
|
Surgical site infection defined per ACS NSQIP criteria
|
within 30 days postoperative
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stephen B Shapiro, MD, Gundersen Health System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2-15-10-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Site Infections
-
Region SkaneVinnovaCompleted
-
Universität LuzernNot yet recruitingSurgical Site Infection | Surgical Site Infections | Colon SurgerySwitzerland
-
Milton S. Hershey Medical CenterWithdrawnSurgical Site Infections
-
Dr. Reddy's Laboratories LimitedDuke Clinical Research InstituteCompletedSurgical Site InfectionsUnited States
-
Sheba Medical CenterUnknown
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationCompletedSurgical Site InfectionsSwitzerland
-
Attikon HospitalCompletedSurgical Site Infections
-
Lawson Health Research InstituteKinetic Concepts, Inc.CompletedPostoperative Surgical Site InfectionsCanada
-
Halmstad County HospitalCompleted
-
MinaPharm PharmaceuticalsRecruitingSurgical Site InfectionsEgypt
Clinical Trials on mupirocin ointment
-
David PalmaNot yet recruitingHead and Neck Cancer | Radiation Mucositis | Staphylococcal Aureus InfectionCanada
-
US Department of Veterans AffairsUniversity of Michigan; Saint Joseph Mercy Health SystemCompleted
-
Philippine Dermatological SocietySt. Luke's Medical CenterUnknown
-
Chikara TashiroCompletedInflammatory Bowel Disease | Pancreas Disease | Hepatobiliary DiseaseJapan
-
Jiangxi Provincial Cancer HospitalRecruitingQuality of Life | Nasopharyngeal Carcinoma | Bacterial Colonization | Radiation-induced Oral MucositisChina
-
University of ChicagoCompletedEndophthalmitis | Prophylaxis | Cataract SurgeryUnited States
-
University of Nove de JulhoCompletedRenal Insufficiency, Chronic | PhotochemotherapyBrazil
-
University Health Network, TorontoCompleted
-
University of Santo Tomas Hospital, PhilippinesCompleted
-
Reig Jofre GroupCompleted